Foundayo Just Launched (April 2026)
Foundayo (orforglipron) was FDA-approved on April 1, 2026. As a newly launched medication, specific insurer PA policies are still being established.
- Requirements below are expected based on standard GLP-1 patterns
- Always verify with your specific plan—policies are evolving
- LillyDirect self-pay available now ($149–$299/month) with no PA required
WHAT INSURERS TYPICALLY REQUIRE
Common PA Requirements for Foundayo
Prior authorization (PA) for Foundayo follows standard GLP-1 medication patterns. While specific Foundayo policies are still being established by insurers, here's what you can expect based on existing GLP-1 requirements:
Standard GLP-1 PA Requirements
- BMI ≥30, or BMI ≥27 with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea)
- 6 months of documented lifestyle modification (diet and exercise program records, not just attestation)
- Step therapy—trial of cheaper weight loss medications first (orlistat, phentermine, Contrave, or Qsymia)
- Decision timeline: within 15 days (72 hours if urgent) for most employer and ACA plans (federal maximum)
Foundayo is an oral pill taken once daily with no food restrictions—a key differentiator from other GLP-1 medications. This may affect how insurers position it on formularies, but specific tier placement is still being determined as of April 2026.
What Makes Foundayo Different for PA
| Feature | Foundayo | PA Implication |
|---|---|---|
| Form | Oral pill (daily) | No injection training documentation needed |
| Food restrictions | None | Simpler dosing compliance documentation |
| Mechanism | GLP-1 only (non-peptide) | First small-molecule oral GLP-1—may have different tier placement |
| Approval date | April 1, 2026 | Very new—insurer policies still being established |
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
EXPECTED BASED ON GLP-1 PATTERNS
Requirements by Insurer (April 2026)
Important: Verify With Your Specific Plan
Foundayo launched April 1, 2026. The requirements below are expected based on standard GLP-1 patterns—specific Foundayo policies may differ. Always confirm current requirements with your insurer before submitting PA.
| Insurer | Expected BMI | Step Therapy | Lifestyle Docs | Verify With |
|---|---|---|---|---|
| Aetna | ≥30, or ≥27 with comorbidity | 3-6 months trial expected | 6 months required | Your plan documents |
| BCBS | Varies by state affiliate | 3-month trial typical | 6 months required | State affiliate policy |
| Cigna | ≥30, or ≥27 with comorbidity | 3-month trial expected | 6 months required | Express Scripts portal |
| UnitedHealthcare | ≥30, or ≥27 with comorbidity | Varies by plan | 6 months required | UHC provider portal |
| CVS Caremark | ≥30, or ≥27 with comorbidity | Expected | 6 months required | Check current status |
What counts as a weight-related comorbidity? Type 2 diabetes, hypertension (high blood pressure), dyslipidemia (high cholesterol/triglycerides), cardiovascular disease, or obstructive sleep apnea (OSA).
Timeline: How Long PA Typically Takes
Federal maximums for most employer and ACA plans: within 15 days (72 hours if urgent). CMS's 2026 prior authorization rule (7 days / 72 hours) covers medical services in Medicare Advantage, Medicaid and CHIP, not drugs like Foundayo.[1]
denied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
OBESITY VS. OVERWEIGHT WITH COMORBIDITY
Requirements by Indication
Foundayo is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.[2]
Important Clarification
Foundayo is not separately FDA-approved for type 2 diabetes or obstructive sleep apnea. However, these conditions qualify as comorbidities that allow patients with BMI 27-29.9 to meet the FDA indication.
| Pathway | BMI Required | Additional Requirements | Documentation Needed |
|---|---|---|---|
| Obesity (standard) | ≥30 | None beyond BMI | BMI measurement, lifestyle records, step therapy |
| Overweight + comorbidity | 27-29.9 | Documented comorbidity | BMI + comorbidity diagnosis with ICD-10 codes |
Qualifying Comorbidities
If your BMI is 27-29.9, you need at least one of these weight-related conditions documented in your medical record:
- Hypertension (ICD-10: I10)
- Type 2 diabetes (ICD-10: E11.9)
- Dyslipidemia (ICD-10: E78.5)
- Cardiovascular disease
- Obstructive sleep apnea (ICD-10: G47.33)
OSA as a Comorbidity Pathway
If you have obstructive sleep apnea (OSA), this can serve as the qualifying comorbidity for the BMI 27-29.9 pathway. You'll need:
- Sleep study showing moderate-to-severe OSA (AHI ≥15 events/hour)
- Diagnosis code G47.33 in your medical record
- Standard lifestyle and step therapy documentation
Note: Some insurers that exclude "obesity" coverage may still cover weight management with OSA as a comorbidity. Check your specific plan language.
WHAT TO GATHER BEFORE PA
Documentation Checklist
Most PA denials happen because of incomplete or missing documentation. Before your doctor submits PA, ensure these items are in your medical record:
Foundayo PA Documentation Checklist
Step Therapy Documentation
For each medication you tried before, your records should show:
- Which medication (orlistat, phentermine, Contrave, or Qsymia—some plans may also require prior GLP-1 trial)
- What dose you took (full therapeutic dose)
- How long you tried it (typically need at least 3 months)
- Why it didn't work:
- Didn't lose enough weight (less than 5%)
- Intolerable side effects (specify which ones)
- Medical contraindication
For step therapy details and workarounds, see our step therapy guide.
Letter of Medical Necessity Tips
Weak Letter
"Patient has obesity and would benefit from Foundayo for weight management."
Vague, no specifics, doesn't address criteria
Strong Letter
"Patient (BMI 34.2, documented over 24 months) has failed 3 prior interventions: 6 months supervised diet/exercise (Weight Watchers, Jan-June 2025), 3-month phentermine trial (discontinued due to tachycardia), and Contrave trial (inadequate response, less than 3% weight loss after 12 weeks). Obesity-related hypertension requires two medications. A1C 6.1% indicates prediabetes. Orforglipron's oral formulation without food restrictions improves likely adherence."
Specific BMI, documented timeline, exact medications with doses, specific failure reasons
WHAT TO EXPECT
The PA Process Timeline
For most employer and ACA plans, federal claims rules set these maximum response times for a drug prior authorization (state law can set shorter limits for state-regulated plans):
Note: CMS's 2026 prior authorization rule (CMS-0057-F, 7 days / 72 hours) covers medical services in Medicare Advantage, Medicaid and CHIP and excludes drugs, so it doesn't apply to Foundayo. Medicare Part D and the Medicare GLP-1 Bridge have their own timelines.[1]
| Request Type | Response Deadline (employer and ACA plans) | When to Use |
|---|---|---|
| Standard | Up to 15 days (one 15-day extension allowed) | Most PA requests |
| Urgent/Expedited | 72 hours | When delay could seriously jeopardize health |
What Happens After Submission
Submission
Your doctor submits PA request with all documentation to your insurer.
Review
Insurer reviews against their PA criteria. They may request additional documentation.
Decision
Approved: You can fill your prescription. Denied: You receive a denial letter with the specific reason.
If Denied: Appeal
Many appeals succeed when properly documented. See our appeals guide.
While You're Waiting
- Keep gathering supporting documentation
- Ask your doctor's office to follow up after 5 business days
- If urgent, request expedited review (72 hours deadline for most employer and ACA plans)
- Consider LillyDirect self-pay ($149–$299/month) as backup
YOUR OPTIONS
What If You Don't Meet Requirements?
If you don't meet your insurer's PA criteria—or your documentation doesn't prove it—here are your options:
Fill Documentation Gaps
Work with your doctor to gather missing documentation. If you haven't completed 6 months of lifestyle modification, start now and document everything. If labs are outdated, get new ones.
Request Step Therapy Exception
If you have medical contraindications to required medications, or documented prior failures, your doctor can request an exception. All major insurers allow these with proper documentation.
Document Comorbidities
If your BMI is 27-29.9, ensure qualifying comorbidities are properly diagnosed and coded. A sleep study for OSA or updated labs showing prediabetes may open the comorbidity pathway.
Appeal the Denial
Many appeals succeed when properly documented. If you believe you meet criteria but were denied, appeal with additional documentation addressing the specific denial reason. See our appeals guide.
Consider Self-Pay
If coverage isn't possible, LillyDirect offers Foundayo at $149–$299/month with no PA required. The Foundayo Savings Card can reduce costs to as little as $25/month if you have commercial insurance coverage.
Self-Pay Pricing (No PA Required)
| Dose | LillyDirect Price |
|---|---|
| 0.8mg | $149/month |
| 2.5mg | $149/month* |
| 5.5mg | $199/month* |
| 9mg | $299/month |
| 14.5mg, 17.2mg | $299/month** |
*Temporary price through December 31, 2026. **Only when refilled within 45 days; otherwise $349/month. Full pricing details
denied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
WHAT'S HAPPENING THIS YEAR
Foundayo PA Outlook: 2026
Foundayo launched April 1, 2026. Here's what to expect as insurer policies evolve:
CMS 2026 Prior Authorization Rule (Effective Jan 1, 2026)
New CMS rule (CMS-0057-F): From January 1, 2026, Medicare Advantage, Medicaid and CHIP must decide medical prior authorizations within 7 days (72 hours if urgent); the rule excludes drugs, so it does not change Foundayo prior authorization timelines.[1]
Medicare GLP-1 Bridge Program (live now)
Foundayo is covered by the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) for $50 per monthly fill, if you have eligible Part D coverage and meet CMS’s eligibility criteria. Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization.[3]
Insurer Formulary Decisions
Major insurers are still finalizing Foundayo formulary placement. As a new drug, expect:
- Initial placement on specialty or non-preferred tiers
- Prior authorization requirements for most plans
- Possible step therapy requiring trial of other GLP-1s first
We'll update this page as insurers announce Foundayo-specific policies.
What Should You Do Now?
- Contact your insurer to ask about Foundayo coverage and PA requirements
- Start gathering documentation now—6 months of lifestyle records takes time
- Consider LillyDirect ($149–$299/month) if PA timeline is uncertain
- Watch for Medicare guidance if you're a Part D beneficiary
- Document everything—comprehensive records support initial PA and any appeals
PA REQUIREMENTS
Frequently Asked Questions
Most insurers require BMI ≥30 (or ≥27 with comorbidity), 6 months of documented lifestyle modification, and step therapy (trying cheaper medications first). Since Foundayo just launched in April 2026, specific insurer policies are still being established—verify requirements with your specific plan.
The FDA indication requires BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea). Some insurers may have stricter thresholds—always verify with your plan.
Most commercial insurers require step therapy for GLP-1 medications, meaning you must try and document failure of cheaper weight loss medications first. Typical step therapy drugs include orlistat, phentermine, Contrave, or Qsymia. Your doctor can request a step therapy exception if you have documented contraindications or prior failures.
Typically required: BMI measurement within last 3 months, 6 months of lifestyle modification records (actual program records, not just attestation), comorbidity documentation with ICD-10 codes (if BMI 27-29.9), prior medication trial records (drug, dose, duration, failure reason), and a physician letter of medical necessity.
For most employer and ACA plans, federal rules require a decision within 15 days (one 15-day extension allowed), and many plans decide sooner when documentation is complete; urgent requests must be decided within 72 hours. If you're denied and appeal, the plan must decide the internal appeal within 30 days.
Options include: documenting qualifying comorbidities to use the BMI ≥27 pathway, appealing with strong medical necessity documentation, or using LillyDirect self-pay ($149–$299/month) which requires no prior authorization.
Yes, through LillyDirect self-pay. Prices currently range from $149/month (0.8mg) to $299/month (highest doses, refilled within 45 days; $349 if late). The Foundayo Savings Card can reduce costs to as little as $25/month if you have commercial insurance coverage.
Yes, with conditions. Foundayo is covered by the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) for $50 per monthly fill, if you have Part D coverage and meet CMS’s eligibility criteria. By law, basic Part D coverage excludes drugs used for weight loss; the Bridge is a separate CMS program.
YOUR PATH FORWARD
What's Next
References
- Centers for Medicare & Medicaid Services. (2024). "CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)." Effective January 1, 2026. cms.gov
- Eli Lilly and Company. (2026). "Lilly's Foundayo (orforglipron) Receives FDA Approval for Chronic Weight Management." Investor News Release, April 1, 2026. investor.lilly.com
- Kaiser Family Foundation. (2026). "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid." Background on the BALANCE model and the Medicare GLP-1 Bridge (now live July 1, 2026 – December 31, 2027; Foundayo is a Bridge drug). kff.org
- Cigna Healthcare. "Prior Authorization Coverage Policies — search for 'GLP-1 weight loss' criteria." cigna.com
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.